ОбзорГрафикПрофильОсновная статистикаФинансовые показателиНовостиTraderScreen

FORTIS INC./  CA3495531079  /

Lang & Schwarz
15.11.2024  18:20:37 Изменение -0.250 Объем сделки Бид18:20:37 Предложение18:20:37 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
41.640EUR -0.60% -
Оборот: -		 41.640Величина цены спроса: - 41.810Величина цены предложения: - 20.56 млрдEUR - -
GlobeNewswire 07.08 Alpha Pro Tech, Ltd. Announces Second Quarter 2024 Financial Results
GlobeNewswire 06.08 FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 31.07 Fortis Inc. Releases Second Quarter 2024 Results and 2024 Sustainability Report
GlobeNewswire 31.07 Fortis Inc. Announces Third Quarter Dividends – 2024
GlobeNewswire 23.07 Advisory: Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire 02.07 Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire 24.06 AstriVax enters clinical phase with its novel vaccine platform technology
GlobeNewswire 18.06 TRIUMPH UNVEILS BONNEVILLE T120 ELVIS PRESLEY LIMITED EDITION
GlobeNewswire 18.06 FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program ...
GlobeNewswire 10.06 Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire 23.05 FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) ...
GlobeNewswire 15.05 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
GlobeNewswire 08.05 Alpha Pro Tech, Ltd. Announces First Quarter 2024 Financial Results
GlobeNewswire 06.05 FibroGen Reports First Quarter 2024 Financial Results
GlobeNewswire 01.05 Fortis Inc. Releases First Quarter 2024 Results
GlobeNewswire 24.04 Advisory: Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold...
GlobeNewswire 24.04 FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combinat...
GlobeNewswire 23.04 Maryland CareerQuest Connects Area Students with Training and Education Opportunities for Hands-On C...
GlobeNewswire 03.04 Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold Annual an...
GlobeNewswire 02.04 FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metast...
GlobeNewswire 28.03 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ...
GlobeNewswire 19.03 AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
GlobeNewswire 13.03 Alpha Pro Tech, Ltd. Announces Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 11.03 Fortis Inc. Releases 2024 Climate Report
GlobeNewswire 01.03 Sage Transform 2024 Unveils Sage Copilot and Introduces Groundbreaking Tech Innovations, Product Enh...